{"product_id":"vygon-bcg-matrix","title":"Vygon S.A. Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVygon S.A.’s BCG Matrix preview highlights a mix of mature medical-device lines likely sitting between Cash Cows and Question Marks, reflecting steady market share in core products and growth potential in specialty disposables; competitive pressure and innovation pace will determine reallocation needs. Purchase the full BCG Matrix for a quadrant-by-quadrant breakdown, actionable resource-allocation guidance, and ready-to-use Word and Excel files to drive smarter investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeonatal PICC Lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVygon holds ~35–40% share in the neonatal PICC (peripherally inserted central catheter) market, a segment growing ~6–8% CAGR through 2028 as NICU standards rise and preterm survival improves; neonatal PICCs contributed an estimated €45–60m to group sales in FY2024.\u003c\/p\u003e\n\u003cp\u003eHigh-tech neonatal PICCs need \u0026gt;10% of product-line revenue reinvested in R\u0026amp;D annually to fend off emerging competitors and meet regulatory demands; unit ASPs (average selling prices) rose ~4% in 2023 due to material and tech upgrades.\u003c\/p\u003e\n\u003cp\u003eRising birth rates in parts of Asia and Africa and protocol shifts to minimally invasive access support continued volume growth—procedural volume up ~5% y\/y in 2024—so the category generates strong cash but needs sustained capex to become a long-term cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNutrisafe2 Enteral Feeding Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNutrisafe2 Enteral Feeding Systems, Vygon S.A.’s proprietary neonatal line, is a market leader in safety with an estimated 35% share of safety-conscious NICU supply contracts in Europe as of 2024 and 22% global share in specialized neonatal hubs.\u003c\/p\u003e\n\u003cp\u003eStricter hospital safety regs (EU Regulation 2017\/745 uptake, US Joint Commission alerts) create a 9–12% CAGR addressable market through 2028, favoring Nutrisafe2’s non-interchangeable connectors.\u003c\/p\u003e\n\u003cp\u003eIt requires continued cash for global marketing and distribution—Vygon reported ~€18m capex and SG\u0026amp;A to scale devices in 2024—so Nutrisafe2 behaves like a high-growth, cash-consuming Star.\u003c\/p\u003e\n\u003cp\u003eSustained investment is vital to secure adoption before maturity; capture targets: 40–45% EU NICU penetration and 25–30% APAC penetration by 2028 to justify continued spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntimicrobial Vascular Access Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAntimicrobial vascular access devices are a cash cow in Vygon S.A.’s BCG matrix: adoption grew ~18% CAGR 2019–2024, and Vygon holds ~22% EU market share in 2024 per IQVIA, driven by infection-prevention mandates that cut catheter-related bloodstream infections by ~40% and save €6–12k per case.\u003c\/p\u003e\n\u003cp\u003eSector growth outpaces traditional vascular access (projected 10% vs 4% CAGR 2025–30), so these devices are poised to become Vygon’s primary revenue engine as hospitals phase out unprotected lines.\u003c\/p\u003e\n\u003cp\u003eHigh manufacturing costs (coating adds ~€4–8 per unit) and specialized sales teams require sustained R\u0026amp;D and SG\u0026amp;A funding; competing with Medtronic and Becton Dickinson forces heavier capex to maintain a 15–20% gross-margin target.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Oncology Ports\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncology ports are a Star: European market-share leadership for Vygon’s implantable ports—estimated 20–25% share in 2025—driven by aging populations and earlier cancer detection raising infusion volumes ~4–6% annually.\u003c\/p\u003e\n\u003cp\u003eVygon’s needle‑shielding tech is a technical leader and is scaling into North America and Asia, but requires high marketing and training spend (~5–7% of segment sales) to educate surgeons and oncology nurses.\u003c\/p\u003e\n\u003cp\u003eAs penetration rises, margins should expand; expected to transition to Cash Cow within 3–5 years as unit volumes grow and education costs normalize.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 EU share ~20–25%\u003c\/li\u003e\n\u003cli\u003eSegment growth ~4–6% CAGR\u003c\/li\u003e\n\u003cli\u003eMarketing\/training ~5–7% of sales\u003c\/li\u003e\n\u003cli\u003ePath to Cash Cow in 3–5 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Regional Anesthesia Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVygon S.A.’s Advanced Regional Anesthesia Kits are high-growth, high-margin products used for precise nerve blocks; Vygon led niche European shares at ~28% in 2024 and saw regional anesthesia kit sales grow ~22% YoY to €34.5m.\u003c\/p\u003e\n\u003cp\u003eShifts from general to regional anesthesia (estimated 6–8% annual uptake in EU hospitals through 2028) create demand, but global expansion needs aggressive marketing and distribution investments.\u003c\/p\u003e\n\u003cp\u003eOngoing capital needed to enhance ultrasound-compatible features; R\u0026amp;D spend on anesthesia devices rose 14% in 2024, and Vygon should target a 10–12% capex increase to stay competitive.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share: ~28% Europe (2024)\u003c\/li\u003e\n\u003cli\u003eSales: €34.5m, +22% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eEU uptake: 6–8% annual growth (to 2028)\u003c\/li\u003e\n\u003cli\u003eRecommended capex rise: +10–12%\u003c\/li\u003e\n\u003cli\u003ePriority: ultrasound compatibility, global promotion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVygon’s Stars: Dominant neonatal PICCs, Nutrisafe2, oncology ports \u0026amp; booming anesthesia kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVygon’s neonatal PICCs, Nutrisafe2, oncology ports and regional anesthesia kits are Stars: neonatal PICCs ≈35–40% EU share, €45–60m FY2024; Nutrisafe2 ≈35% EU safety contracts, €18m 2024 scale spend; oncology ports 20–25% EU (2025), 4–6% CAGR; anesthesia kits €34.5m +22% YoY, 28% EU. Continued R\u0026amp;D\/marketing capex required to secure 2028 penetration targets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eSales 2024\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeonatal PICC\u003c\/td\u003e\n\u003ctd\u003e35–40%\u003c\/td\u003e\n\u003ctd\u003e€45–60m\u003c\/td\u003e\n\u003ctd\u003e6–8% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutrisafe2\u003c\/td\u003e\n\u003ctd\u003e35% EU\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e9–12% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology ports\u003c\/td\u003e\n\u003ctd\u003e20–25%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e4–6% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnesthesia kits\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e€34.5m\u003c\/td\u003e\n\u003ctd\u003e22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise BCG review of Vygon S.A.: identifies Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest guidance and trend context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each Vygon S.A. business unit in a quadrant for fast strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Peripheral IV Cannulas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard peripheral IV cannulas form Vygon S.A.’s cash-cow segment, with an estimated 2024 market share of ~18% in Europe and ~€120m revenue from IV devices, reflecting stable, low-growth demand.\u003c\/p\u003e\n\u003cp\u003eWell-established tech cuts R\u0026amp;D and promo spend to under 5% of sales, enabling high cash extraction that funds 2024–25 Star and Question Mark projects totalling ~€40m in planned investment.\u003c\/p\u003e\n\u003cp\u003eFocus remains on manufacturing efficiency and supply-chain cost cuts (target 3–5% margin improvement) to sustain high-volume margins in this mature line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic Respiratory Circuits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVygon’s basic respiratory circuits—standard ventilator tubing and oxygen therapy sets—sit in a mature global hospital market with steady demand: estimated annual sales ~€45–55m (2024) and penetration \u0026gt;60% in EU acute-care hospitals.\u003c\/p\u003e\n\u003cp\u003eGrowth is low (~1–2% CAGR); Vygon focuses on cost per unit reductions (targeting 8% manufacturing OPEX cut in 2025) to maximize cash flow rather than product R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eThese lines generate predictable EBITDA margins (~18–22%) and annual free cash flow ~€8–12m, funding debt service and maintaining a dividend yield near 3% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConventional Surgical Suction Sets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe European market for basic surgical suction systems is saturated with ~1% annual growth, yet Vygon S.A. retains ~18–22% share among hospital buyers as of 2025, remaining a preferred supplier for many providers.\u003c\/p\u003e\n\u003cp\u003eThese low-tech suction sets are reliable workhorses with \u0026lt;1% failure rates and minimal maintenance, producing operating margins near 28% and net cash conversion positive.\u003c\/p\u003e\n\u003cp\u003eBrand loyalty and clinical protocols cut marketing spend to ~2% of sales while keeping share high, so cash is routinely redirected to neonatal R\u0026amp;D—about €6–8M annually in 2024–25.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Enteral Syringes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStandard enteral syringes are cash cows for Vygon S.A., generating steady revenue from mature, high-volume lines while safety-engineered syringes take the growth role.\u003c\/p\u003e\n\u003cp\u003eThey serve broad home-care and hospital markets needing low-cost feeding supplies; global enteral device demand was ~€1.1bn in 2024 with reusable consumables ~4–6% annual unit growth.\u003c\/p\u003e\n\u003cp\u003eVygon’s edge is long-standing distribution, ISO 13485 quality, and low capex—typical operating margins ~18–25% on these SKUs—freeing cash for R\u0026amp;D and Stars.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh volume, low growth\u003c\/li\u003e\n\u003cli\u003eBroad home-care\/hospital demand\u003c\/li\u003e\n\u003cli\u003eEstablished distribution + ISO 13485\u003c\/li\u003e\n\u003cli\u003eLow capex; ~18–25% margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTraditional Thoracic Drainage Bags\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVygon S.A.’s Traditional Thoracic Drainage Bags sit in the BCG Matrix cash cows quadrant: market growth ~1% annually and Vygon market share ~35% in Europe (2024 sales €18m), stable demand and few new entrants keep it dominant.\u003c\/p\u003e\n\u003cp\u003eHigh margins (EBIT margin ~28% in 2024) come from fully depreciated lines and lean logistics, funding R\u0026amp;D: cash flows supported €4–5m pa redirected to digital health pilots since 2022.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket growth ~1% (2024)\u003c\/li\u003e\n\u003cli\u003eVygon share ~35% (Europe, 2024)\u003c\/li\u003e\n\u003cli\u003e2024 sales ≈ €18m\u003c\/li\u003e\n\u003cli\u003eEBIT margin ≈ 28% (2024)\u003c\/li\u003e\n\u003cli\u003eAnnual cash redirected €4–5m to digital projects\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVygon's €300–330m cash cows: high-share, low-growth staples delivering strong margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVygon’s cash cows: IV cannulas, basic respiratory circuits, suction systems, enteral syringes, thoracic drainage bags—high share, low growth (≈1–2% CAGR), 2024 combined sales ≈€300–330m, EBITDA margins 18–28%, annual free cash flow ≈€20–27m funding €40m 2024–25 investments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 sales (€m)\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eEBITDA %\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIV cannulas\u003c\/td\u003e\n\u003ctd\u003e120\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRespiratory\u003c\/td\u003e\n\u003ctd\u003e50\u003c\/td\u003e\n\u003ctd\u003e60%+\u003c\/td\u003e\n\u003ctd\u003e19%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSuction\u003c\/td\u003e\n\u003ctd\u003e30\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnteral\u003c\/td\u003e\n\u003ctd\u003e40\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThoracic\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eVygon S.A. BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Vygon S.A. BCG Matrix report you'll receive after purchase—no watermarks or demo text, just the final, fully formatted document ready for strategic use.\u003c\/p\u003e\n\u003cp\u003eThis preview matches the downloadable file precisely, crafted with market-backed analysis and clear visuals to support your portfolio and product decisions.\u003c\/p\u003e\n\u003cp\u003eUpon purchase you’ll get the identical, editable file instantly—suitable for printing, presenting, or integrating into client materials.\u003c\/p\u003e\n\u003cp\u003eNo mockups or placeholders—just a professional BCG Matrix report designed for immediate application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748503138681,"sku":"vygon-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/vygon-bcg-matrix.png?v=1772208847","url":"https:\/\/growthsharematrix.com\/products\/vygon-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}